Intrahepatic cholangiocarcinoma (iCCA), the second most common primary liver cancer after hepatocellular carcinoma, remains one of the most challenging malignancies to treat due to its highly ...

Intrahepatic cholangiocarcinoma (iCCA), the second most common primary liver cancer after hepatocellular carcinoma, remains one of the most ...

A routine blood report often brings relief. Numbers fall within range, the doctor nods, and life moves on. Yet, many people ...

Professor David Kerr warns against 'treating the marker' in CRC. Should rising ctDNA trigger chemo without radiologic proof?

Detailed price information for Bolt Biotherapeutics Inc (BOLT-Q) from The Globe and Mail including charting and trades.

Research shows tumor debulking in advanced colorectal cancer does not enhance survival outcomes and may increase adverse ...

(Nanowerk Spotlight) A cancer cell can shed telltale proteins into the bloodstream long before a tumor becomes visible on a scan. But finding those molecules is like searching for a handful of sand ...

Of all the types of breast cancer, triple negative breast cancer (TNBC) is the most aggressive and lacks specific therapies. TNBC also is more likely to metastasize, or travel through the blood stream ...

PLYMOUTH, Minn.--(BUSINESS WIRE)--VizMark has received U.S. Food and Drug Administration FDA 510k clearance for VM1, a non-metal visual tumor marker designed to provide artifact-free visibility across ...

VizMark has received U.S. Food and Drug Administration FDA 510k clearance for VM1, a non-metal visual tumor marker designed to provide artifact-free visibility across all major breast imaging ...

A new AI tool called DOLPHIN exposes hidden genetic markers inside single cells, enabling earlier detection and more precise treatment choices. It also sets the stage for building virtual models of ...